$TCRT
Alaunos Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515284805 Filed on August 10, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $1.870M $270.0K $200.0K
YoY Change 196.83% 35.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.070M $7.070M $3.030M
YoY Change 8.1% 133.33% -18.55%
% of Gross Profit
Research & Development $16.97M $7.424M $8.346M
YoY Change 74.36% -11.05% -43.51%
% of Gross Profit
Depreciation & Amortization $60.00K $120.0K $100.0K
YoY Change -50.0% 20.0% -50.0%
% of Gross Profit
Operating Expenses $16.97M $7.424M $8.346M
YoY Change 74.36% -11.05% -43.51%
Operating Profit -$18.17M -$14.23M -$11.18M
YoY Change 52.12% 27.27% -38.91%
Interest Expense $0.00 $0.00 $5.600M
YoY Change -100.0% -100.0% -1500.0%
% of Operating Profit
Other Income/Expense, Net -$4.000K $14.00K $1.000K
YoY Change -300.0% 1300.0% -85.71%
Pretax Income -$18.17M -$14.21M -$5.580M
YoY Change 198.36% 154.66% -70.14%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$18.17M -$14.21M -$5.576M
YoY Change 198.21% 154.86% -70.17%
Net Earnings / Revenue -971.66% -5263.33% -2788.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.14 -$0.11 -$0.06
COMMON SHARES
Basic Shares Outstanding 130.9M shares 128.2M shares 100.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $163.8M $118.6M $53.00M
YoY Change 255.31% 123.77% 36.25%
Cash & Equivalents $163.8M $118.6M $53.00M
Short-Term Investments
Other Short-Term Assets $8.300M $4.400M $1.000M
YoY Change 453.33% 340.0% -75.61%
Inventory
Prepaid Expenses
Receivables $400.0K $100.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.5M $123.1M $54.02M
YoY Change 260.73% 127.82% 25.55%
LONG-TERM ASSETS
Property, Plant & Equipment $262.0K $321.0K $683.0K
YoY Change -59.94% -53.0% -60.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $491.0K $509.0K $513.0K
YoY Change -4.29% -0.78% -29.92%
Total Long-Term Assets $881.0K $958.0K $1.324M
YoY Change -31.97% -27.64% -48.54%
TOTAL ASSETS
Total Short-Term Assets $172.5M $123.1M $54.02M
Total Long-Term Assets $881.0K $958.0K $1.324M
Total Assets $173.4M $124.0M $55.35M
YoY Change 253.01% 124.11% 21.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.154M $3.143M $447.0K
YoY Change 112.7% 603.13% -61.63%
Accrued Expenses $18.14M $8.752M $7.773M
YoY Change 132.45% 12.59% -59.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.63M $13.11M $10.79M
YoY Change 153.22% 21.52% -48.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $49.90M $17.00K $20.00K
YoY Change 249400.0% -15.0% -99.22%
Total Long-Term Liabilities $49.90M $17.00K $20.00K
YoY Change 249400.0% -15.0% -99.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.63M $13.11M $10.79M
Total Long-Term Liabilities $49.90M $17.00K $20.00K
Total Liabilities $79.52M $13.60M $17.63M
YoY Change 529.51% -22.88% -32.88%
SHAREHOLDERS EQUITY
Retained Earnings -$483.2M -$465.1M -$356.1M
YoY Change 33.41% 30.59%
Common Stock $577.1M $575.5M $390.3M
YoY Change 44.74% 47.45% 17.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.84M $110.4M $37.72M
YoY Change
Total Liabilities & Shareholders Equity $173.4M $124.0M $55.35M
YoY Change 253.01% 124.11% 21.37%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$18.17M -$14.21M -$5.576M
YoY Change 198.21% 154.86% -70.17%
Depreciation, Depletion And Amortization $60.00K $120.0K $100.0K
YoY Change -50.0% 20.0% -50.0%
Cash From Operating Activities $45.20M -$11.69M -$7.640M
YoY Change -530.89% 53.01% -54.31%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00 $100.0K
YoY Change -88.89% -100.0% 900.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00 -$100.0K
YoY Change -88.89% -100.0% 900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 560.0K 350.0K
YoY Change -97.57% 60.0%
NET CHANGE
Cash From Operating Activities 45.20M -11.69M -7.640M
Cash From Investing Activities -10.00K 0.000 -100.0K
Cash From Financing Activities 90.00K 560.0K 350.0K
Net Change In Cash 45.28M -11.13M -7.390M
YoY Change -758.14% 50.61% -55.83%
FREE CASH FLOW
Cash From Operating Activities $45.20M -$11.69M -$7.640M
Capital Expenditures $10.00K $0.00 $100.0K
Free Cash Flow $45.19M -$11.69M -$7.740M
YoY Change -527.13% 51.03% -53.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130852061 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53001000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3491349 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3543331 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.12
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3635802 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.12
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130822034 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1912531 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.23
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130822034 shares
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13110000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8752000
CY2015Q2 us-gaap Liabilities
Liabilities
13597000
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
399000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
131000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
575364000
CY2015Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
869000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
816000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-465054000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
470000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
110441000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124038000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3143000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
123080000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
27534000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
27130000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118550000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15074000
CY2015Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
89000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4200000
CY2015Q2 us-gaap Assets
Assets
124038000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4441000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
509000
CY2015Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6505663 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.10
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104452105 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3781162 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104452105 shares
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10826000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7182000
CY2014Q4 us-gaap Liabilities
Liabilities
11396000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
104000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
406349000
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
850000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1360000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372612000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
570000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
33841000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45237000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2004000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
531000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44087000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4130000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2014Q4 us-gaap Assets
Assets
45237000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q2 ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
3750000
CY2015Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
In connection with such transfer, the terms of the MD Anderson License also require the Company and Intrexon to enter into a research and development agreement with MD Anderson pursuant to which the Company will provide funding for certain research development, preclinical and clinical activities of MD Anderson for a period of three years
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
104300 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16833125 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16289000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100326416 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99000
us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
132000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20961000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-113000
us-gaap Interest Paid
InterestPaid
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-957000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000
us-gaap Net Income Loss
NetIncomeLoss
-15287000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5682000
us-gaap Contracts Revenue
ContractsRevenue
400000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
305000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
217000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1185000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6473000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1416000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-98000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-99000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1317000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21361000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15203000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
62000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25000
us-gaap Share Based Compensation
ShareBasedCompensation
2435000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14888000
ziop Revenue Recognition Period
RevenueRecognitionPeriod
P75M
ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
43300 shares
ziop Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
21977 shares
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ZIOP
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
51800 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4666848 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
153833 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y5M27D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.11
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21411000
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2860299 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.59
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120953279 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y10M21D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M4D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Stock Issued1
StockIssued1
67285000
us-gaap Payments For Repurchase Of Other Equity
PaymentsForRepurchaseOfOtherEquity
246000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94320000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4577000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Operating Income Loss
OperatingIncomeLoss
-92452000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-55000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
67285000
us-gaap Interest Paid
InterestPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3140000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3302000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
18000
us-gaap Net Income Loss
NetIncomeLoss
-92442000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000
us-gaap Contracts Revenue
ContractsRevenue
544000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
477000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
236000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97180000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11323000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
92996000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-544000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
75747000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
246000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1138000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
34000
us-gaap Share Based Compensation
ShareBasedCompensation
4577000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1569000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
267000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
19000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3140000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81673000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
17000
ziop Common Stock Warrants Expiration Date
CommonStockWarrantsExpirationDate
2014-12
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
23800 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198 pure
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.84
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100422564 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8557 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9407 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11177000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-5576000
CY2014Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5600000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3031000
CY2014Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
11377000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1212000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8346000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1800 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0169 pure
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.85
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
128413417 shares
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14225000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-14211000
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
272000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7073000
CY2015Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14497000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3485000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7424000

Files In Submission

Name View Source Status
0001193125-15-284805-index-headers.html Edgar Link pending
0001193125-15-284805-index.html Edgar Link pending
0001193125-15-284805.txt Edgar Link pending
0001193125-15-284805-xbrl.zip Edgar Link pending
d34504d10q.htm Edgar Link pending
d34504dex311.htm Edgar Link pending
d34504dex312.htm Edgar Link pending
d34504dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g34504page003.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20150630.xml Edgar Link completed
ziop-20150630.xsd Edgar Link pending
ziop-20150630_cal.xml Edgar Link unprocessable
ziop-20150630_def.xml Edgar Link unprocessable
ziop-20150630_lab.xml Edgar Link unprocessable
ziop-20150630_pre.xml Edgar Link unprocessable